GET DAILY SIGNALSWhy Is ICU Medical (ICUI) Stock Down -1.23% Today?
Key Takeaways
- ICUI shares were down roughly 1.23% in early trading, pulling back to about $179.87 after closing the prior session at $182.11.
- The move reflects modest profit-taking after a strong multi-day, post-earnings advance rather than any single negative company-specific headline.
- A bullish earnings backdrop — a third-quarter revenue and adjusted-EPS beat and reaffirmed full-year guidance — continues to support the stock's recent run.
- Analyst price-target increases and Buy/Overweight ratings following the report have underpinned sentiment, though momentum is cooling today.
- Traders are watching whether the stock holds its recent breakout levels and how broader healthcare and medtech names trade into the session.
- For deeper detail on valuation, upcoming reports, and forward-looking signals, explore Price Targets, Earnings, and Forecast pages for ICUI.
- To see how AI-driven strategies are positioning in real time, browse Tickeron's curated Trending AI Robots.
Opening Summary
ICU Medical, Inc. (ICUI) — a San Clemente, California-based medical device maker focused on infusion therapy, vascular access, and vital care products — traded lower in Tuesday's session. The stock slipped about 1.23%, or roughly $2.24, to around $179.87 from a prior close of $182.11. The modest decline comes on the heels of a sharp multi-session rally, suggesting the move is best characterized as consolidation and profit-taking following a strong post-earnings run rather than a response to a new, company-specific development.
Post-Earnings Momentum Cools
The clearest driver behind today's move is the simple fact that ICUI shares have run up substantially in recent sessions. After reporting third-quarter results on November 5, the stock advanced through several consecutive sessions, climbing from below $168 to a close of $182.11 on November 10. Against that backdrop, a small pullback is typical as short-term traders lock in gains and the stock digests its recent gains. The decline in early trading is consistent with consolidation rather than a reversal of the underlying fundamental story.
A Strong Earnings Backdrop
The selling pressure is occurring against a fundamentally supportive backdrop. For the third quarter of 2026, ICU Medical reported revenue of about $560.4 million, above consensus estimates of roughly $552.1 million, and adjusted earnings per share of $2.44, comfortably ahead of the $2.15 analysts had expected. Management also reaffirmed full-year guidance and pointed toward the high end of its prior adjusted-EBITDA and adjusted-EPS ranges. Infusion Systems grew at a double-digit rate, while Consumables posted record absolute sales, helping offset softer Vital Care results tied to logistics-consolidation disruptions. This earnings-driven strength helps explain why the stock has been resilient overall, even as it gives back a fraction of its gains today.
Analyst Support and Insider Activity
The post-earnings period brought a wave of supportive analyst commentary, with several firms raising price targets while maintaining Buy or Overweight ratings, citing continued upside in Infusion Systems and improving margins. That bullish tilt has supported the stock's advance. At the same time, recent regulatory filings showing insider selling by executives and board members have added a modest counterweight to sentiment, giving some investors a reason to trim positions. Neither factor appears to be the primary catalyst for today's move, but together they frame a market that is balancing strong fundamentals against profit-taking near recent highs.
Market Context and Trading Activity
Today's decline is modest and arrived on relatively light early-session volume, reinforcing the view that it is a routine pullback rather than a broad-based selloff. The move is not tied to any new recall, regulatory, or earnings headline. In recent weeks, ICUI has benefited from a broader bid for healthcare and medical-technology names, and the stock's sensitivity to sector rotation means it can drift lower when that risk-on momentum stalls. Traders are watching whether the shares can hold above their recent breakout levels after the strong run that followed the third-quarter report.
What Comes Next for ICUI
Looking ahead, investors will focus on ICU Medical's ability to execute on its margin-expansion roadmap — including its target of a 43% gross margin — and on the integration of its consolidated logistics network, which management expects to improve sequentially in the fourth quarter. Product milestones, such as the regulatory filing for the Medfusion 5000 syringe pump and new infusion consumables launches, are also on the radar. Macro factors including tariffs, inflation, and currency volatility remain key risks to margins and cash flow. The company's next quarterly report is expected in early 2027, and until then, the stock is likely to be driven by execution news, sector sentiment, and broader market conditions.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to monitor. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ICUI in upward trend: 10-day moving average broke above 50-day moving average on October 30, 2026
The 10-day moving average for ICUI crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ICUI as a result. In 63 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ICUI just turned positive on November 04, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 31 of 51 cases over the following month. The odds of a continued upward trend are 61%.
ICUI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 189 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 154 of 204 cases where ICUI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
ICUI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.000) is normal, around the industry mean (4.964). ICUI has a moderately high P/E Ratio (143.425) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is the Profit Rate for the Ascending Triangle (Bullish) Pattern?
How Do Embargoes Impact Global Trade and Diplomacy?
What Is Net Present Value (NPV)?
6 Benefits of Finding Stock Chart Patterns in Real Time
Cyclacel Pharmaceuticals ( CYCC ) Stock Soars 251.95% in Five Days: Catalysts, Correlations, and AI-Driven Trading Opportunities
General Information
a manufacturer of medical technologies
Industry PharmaceuticalsOther
Advertisement